Amarin Corp Plc (AMRN)

[sts66]

After googling some stuff BMS/PFE lost "data protection" on 6/16/2020, but have another two years of protection from generics, then patents must be overturned - this is almost identical to the EU's exclusivity regs, except EU uses 8+1+1, not 6+2:

https://gowlingwlg.com/en/insights-resources/articles/2019/innovative-drugs-data-protection-in-canada/

As part of any new drug submission, undisclosed clinical and non-clinical data must be submitted to Health Canada. Innovative drugs are granted data protection, which prevents generic drug manufacturers from relying on this undisclosed data.

Once registered, generic manufacturers are prevented from filing a drug submission that makes a direct or indirect comparison to the innovator's undisclosed data for a period of six years (the "no file" period). Following the 6-year "no file" period, generic manufacturers are precluded from receiving drug approval for an additional 2 years (the "no approval" period), culminating in eight years of data protection.

If Roadkill is correct about the new patents and they also apply to Canada, Eliquis is safe from generics for many more years. And PFE reps will be co-promoting V and Eliquis.